Inside the Global Effort to Develop Vaccines for the Bundibugyo Ebola Outbreak

Why Bundibugyo Ebola Is Harder to Control

Most recent Ebola outbreaks have been caused by the Zaire ebolavirus, which has an approved vaccine (Ervebo) and other countermeasures. The Bundibugyo species is genetically distinct, and existing vaccines were designed for different viral proteins, meaning they are not approved for Bundibugyo infections.

Because of this gap, the response has relied primarily on classic containment strategies:

• rapid case detection and laboratory confirmation
• patient isolation and supportive care
• contact tracing and monitoring
• infection‑control protocols in hospitals
• safe burial practices and community engagement

These methods remain the main tools to limit spread while new medical countermeasures are developed.

Oxford’s ChAdOx1 BDBV Vaccine Candidate

One of the most closely watched vaccine efforts is being led by the University of Oxford’s Oxford Vaccine Group, which is developing a candidate called ChAdOx1 BDBV.

The vaccine uses the ChAdOx viral‑vector platform, the same technology family used in several pandemic vaccines, where a modified adenovirus delivers genetic instructions that trigger an immune response against Ebola proteins. Oxford researchers say they are rapidly generating the preclinical data needed to move the vaccine toward clinical trials.

To speed production if trials move forward, Oxford is working with several partners, including:

• its Clinical BioManufacturing Facility
• the Serum Institute of India, the world’s largest vaccine manufacturer
• global preparedness organizations such as CEPI

The partnership with the Serum Institute is especially important because it provides the ability to manufacture large numbers of doses quickly if the candidate proves safe and effective.

The Competing rVSV‑Based Vaccine Approach

A second Bundibugyo‑specific vaccine under development uses the recombinant vesicular stomatitis virus (rVSV) platform. This is the same technology used in the licensed Zaire Ebola vaccine Ervebo, but modified to express the Bundibugyo virus glycoprotein instead.

Early research—including non‑human‑primate studies—suggests the candidate could provide protection, but it has not yet entered human clinical trials.

One challenge is manufacturing readiness. According to global vaccine alliance Gavi, no clinical‑trial doses are currently available, and producing them could take six to nine months.

Expected Timelines for Trials

Even with accelerated research, timelines remain uncertain.

Some reports suggest that the Oxford ChAdOx candidate might reach first‑in‑human trials within a few months if preclinical testing proceeds successfully. Broader estimates from health officials indicate that several months to roughly 6–9 months could be required before a vaccine is ready for deployment in outbreak settings.

Those timelines reflect the need to balance speed with safety and regulatory oversight.

Experimental Treatments and Cross‑Protection Research

Unlike the Zaire strain of Ebola, no specific therapeutic drugs are approved for Bundibugyo virus disease.

Researchers and health agencies are therefore considering several experimental approaches, including:

• investigational antivirals such as obeldesivir
• potential monoclonal antibody therapies prioritized for clinical testing
• the experimental use of existing Zaire‑targeting vaccines, which may offer partial cross‑protection based on animal studies

However, these options remain experimental and unproven for Bundibugyo, and any use would likely require emergency or compassionate‑use authorization.

A Race Between Science and Public Health

The Bundibugyo outbreak highlights a persistent challenge in epidemic preparedness: vaccines often exist for one strain of a virus but not for closely related ones.

Until a Bundibugyo‑specific vaccine can be tested and deployed, outbreak control depends largely on rapid detection, isolation, contact tracing, and community‑level public‑health measures.

Meanwhile, the accelerated work on ChAdOx and rVSV vaccine platforms could help close that gap—both for this outbreak and for future filovirus emergencies.

If successful, these efforts may also contribute to a broader goal already underway in vaccine research: developing multivalent vaccines capable of protecting against multiple Ebola species at once, reducing the risk that new outbreaks will again face the same lack of ready countermeasures.